12:08 PM EDT, 07/11/2024 (MT Newswires) -- Salarius Pharmaceuticals ( SLRX ) said Thursday the US Food and Drug Administration has placed a trial evaluating seclidemstat in combination with azacitidine in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia on partial clinical hold.

This comes after a patient in the University of Texas MD Anderson Cancer Center's sponsored clinical trial experienced "a serious and unexpected" grade-4 adverse event, according to a filing with the US Securities and Exchange Commission.

Under the hold, no new patients may be enrolled, though already enrolled subjects may continue treatment and all study procedures if they are benefiting, Salarius said.

The company's shares were down about 22% in recent trading.

Price: 2.12, Change: -0.59, Percent Change: -21.77